Biotech and Pharma Industry News | BioPharma Dive
Get the free daily newsletter read by industry experts. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Meso Scale Discovery (MSD): An immunoassay platform with …
Feb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Radiopharmaceuticals for cancer: Making radiation precise
Aug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
FDA approves new RSV drug to protect infants, toddlers
Jul 17, 2023 · In clinical testing, Beyfortus reduced the risk of medically attended lower respiratory tract disease by 70% in one study, and by 75% in another.A third, larger study showed treatment was 83% effective in preventing hospitalization from RSV-related disease in infants under 1 year of age. AstraZeneca and Sanofi also gathered data supporting the drug’s safety.
Novartis wins FDA approval for new heart drug, but faces uphill …
Dec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400-per-year price that the Institute for Clinical and Economic Review, a watchdog group on drug costs, said would be cost effective for Leqvio when used broadly, but ...
J&J to phase out Janssen name in corporate rebrand
Sep 15, 2023 · Courtesy of Johnson & Johnson. Janssen, a brand name that for six decades has been emblazoned on Johnson & Johnson’s pharmaceutical laboratories and prescription drugs, will be phased out as part of a corporate rebranding in the wake of the healthcare giant splitting in two. Taking its place will be a new name, Johnson & Johnson Innovative ...
BioMarin finally secures FDA approval of hemophilia gene therapy
Jun 29, 2023 · The Food and Drug Administration approved on Thursday the first gene therapy for the most common form of hemophilia, clearing the way for what patients, doctors and the medicine’s developer hope could be a one-time treatment for the rare bleeding disorder. BioMarin Pharmaceutical, the California-based company behind the therapy, plans to sell ...
Pharma News | BioPharma Dive
5 days ago · Novo sinks on obesity drug results; Sanofi reveals anticipated MS data. A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged. By BioPharma Dive staff • Sept. 20, 2024.
Clinical Trial News - BioPharma Dive
5 days ago · Investors are waking up to Centessa’s sleepiness drug. A small, early study produced what one analyst called “highly compelling” results that lifted the company’s shares by as much as 15% Tuesday. By Jacob Bell • Sept. 10, 2024. The latest clinical trial news for biotech and biopharmaceutical professionals.
The biopharma industry outlook on 2024: Guarded optimism for a …
Published Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...